| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 09/18/2001 | US6291491 Treatment of type ii diabetes and obesity; antidepressants; decrease gut motility. |
| 09/18/2001 | US6291490 Methods and compositions for treating conditions caused by excessive calcium influx in cells using optically pure (-) amlodipine |
| 09/18/2001 | US6291485 Treatment of post-ptca restenosis |
| 09/18/2001 | US6291477 Tetrahydroquinolines, processes for their preparation, pharmaceutical compositions containing them, and their use to prevent or treat hyperlipoproteinaemia |
| 09/18/2001 | US6291475 Bispidine antiarrhythmic compounds |
| 09/18/2001 | US6291473 Treating anxiety, depression, post-traumatic stress disorder, inflammatory diseases, obesity, in mammals |
| 09/18/2001 | US6291458 Morpholinobenzamide salts |
| 09/18/2001 | US6291457 Compounds having cytokine inhibitory activity |
| 09/18/2001 | US6291455 Producing an antiangiogenic and/or vascular permeability reducing effect |
| 09/18/2001 | US6291454 Dithiepino[6,5-b]pyridines, and related compositions and methods |
| 09/18/2001 | US6291450 Carboxylic acid substituted heterocycles, derivatives thereof and methods of use |
| 09/18/2001 | US6291437 The protein/nucleic acid compositions are administered in an amount capable of inducing cell mediated immunity and/or antibody response in the subject. |
| 09/18/2001 | US6291425 Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
| 09/18/2001 | US6291211 Expressing heterologous polypeptides in cells; incubate cells with expression vectors, transform cells, express heterologous polypeptide |
| 09/18/2001 | US6291195 Generating ligands which bind preferential human receptors; incubate cells expressing preferential binding protein with modulator, detect adjustment in binding activity |
| 09/18/2001 | US6290985 By chewing the gum, the medicament or agent is released from the product. |
| 09/18/2001 | CA2236814C Quinoline and quinazoline compounds useful in therapy |
| 09/18/2001 | CA2145182C Dna encoding human alpha 1 adrenergic receptors and uses thereof |
| 09/18/2001 | CA2046050C Bis[4-(2,6-di-alkyl)phenol]silane derivatives as antiatherosclerotic agents |
| 09/18/2001 | CA2031385C Extract from ginkgo biloba leaves, its method of preparation and pharmaceuticals containing the extract |
| 09/18/2001 | CA2026890C Quinoline derivatives, their production and use |
| 09/18/2001 | CA1341293C Alpha-subunit of the mac-1 leukocyte adhesion receptor |
| 09/15/2001 | WO2001068859A2 Il-17 receptor like molecules and uses thereof |
| 09/15/2001 | CA2403370A1 Il-17 receptor like molecules and uses thereof |
| 09/13/2001 | WO2001067110A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 09/13/2001 | WO2001066772A2 Heparinase iii and uses thereof |
| 09/13/2001 | WO2001066746A2 G-protein coupled receptor related polypeptides |
| 09/13/2001 | WO2001066742A2 G-protein coupled receptors |
| 09/13/2001 | WO2001066716A1 Polypeptide having phosphodiesterase activity |
| 09/13/2001 | WO2001066706A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066698A1 Human cord blood as a source of neural tissue for repair of the brain and spinal cord |
| 09/13/2001 | WO2001066595A2 Human fgf-23 gene and gene expression products |
| 09/13/2001 | WO2001066594A2 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | WO2001066557A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | WO2001066550A2 Compounds for pdt |
| 09/13/2001 | WO2001066548A1 New aza-indolyl derivatives |
| 09/13/2001 | WO2001066544A2 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | WO2001066543A2 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | WO2001066539A1 Imidazol derivatives as raf kinase inhibitors |
| 09/13/2001 | WO2001066525A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | WO2001066521A1 Azacyclic compounds for use in the treatment of serotonin related diseases |
| 09/13/2001 | WO2001066214A1 Methods for extraction and reaction using supercritical fluids |
| 09/13/2001 | WO2001066164A1 Modified protein matrices |
| 09/13/2001 | WO2001066143A1 Vasoactive agents |
| 09/13/2001 | WO2001066140A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | WO2001066133A1 Leptin-resistance ameliorating agents |
| 09/13/2001 | WO2001066125A1 DNA ENCODING HUMAN ACID-SENSING ION CHANNEL BNaC4 (ASIC4) |
| 09/13/2001 | WO2001066124A2 Composition for the treatment of heart failure |
| 09/13/2001 | WO2001066107A2 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | WO2001066099A2 Use of quinazoline derivatives as angiogenesis inhibitors |
| 09/13/2001 | WO2001066098A2 Therapeutic uses of ppar mediators |
| 09/13/2001 | WO2001066093A2 Sustained release ranolazine formulations |
| 09/13/2001 | WO2001066081A2 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 09/13/2001 | WO2001066043A1 Bulbous valve and stent for treating vascular reflux |
| 09/13/2001 | WO2001030759A3 Sodium-hydrogen exchanger type 1 inhibitor crystals |
| 09/13/2001 | WO2001028993A3 Tyrosine kinase inhibitors |
| 09/13/2001 | WO2001028992A3 New oxabispidine compounds useful in the treatment of cardiac arrhythmias |
| 09/13/2001 | WO2001028498A3 Retro-anandamides, high affinity and stability cannabinoid receptor ligands |
| 09/13/2001 | WO2001028497A3 Novel bicyclic cannabinoid agonists for the cannabinoid receptor |
| 09/13/2001 | WO2001028492A3 Polyanhydrides with biologically active degradation products |
| 09/13/2001 | WO2001026666A3 Composition for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba |
| 09/13/2001 | WO2001019542A8 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/13/2001 | WO2001009169A3 Cysteine protease inhibitors |
| 09/13/2001 | WO2001009138A3 Chemokine receptor antagonists and methods of use therefor |
| 09/13/2001 | WO2000062795A3 UTEROGLOBIN IN THE TREATMENT OF IgA MEDIATED AUTOIMMUNE DISORDERS |
| 09/13/2001 | WO2000059886A3 Benzimidazole abd imidazolophyridine derivaties, their preparation and their use as selective modulators of bradykinin b2 (=bk-2) receptors |
| 09/13/2001 | WO2000034780A8 METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ¿3? |
| 09/13/2001 | US20010021777 Indane or dihydroindole derivatives |
| 09/13/2001 | US20010021772 Vascular endothelial growth factor |
| 09/13/2001 | US20010021758 Drugs, medical diagnosis |
| 09/13/2001 | US20010021708 Acylurea compound containing imidazolidine ring |
| 09/13/2001 | US20010021700 Vectors, host cells, antibodies, and recombinant and synthetic methods for producing polynucleotides and the polypeptides they encode |
| 09/13/2001 | US20010021516 An isolated nucleic acid molecule comprising a polynucleotide having nucleotide sequence atleast 95% identical to a sequence selected from a nucleotide sequence encoding a TRID polypeptide having specific amino acid sequence |
| 09/13/2001 | US20010021397 Solvent extraction from yeast |
| 09/13/2001 | CA2402433A1 Compounds for pdt |
| 09/13/2001 | CA2402315A1 Therapeutic uses of ppar mediators |
| 09/13/2001 | CA2402179A1 Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers |
| 09/13/2001 | CA2402096A1 Vasoactive agents |
| 09/13/2001 | CA2402039A1 3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives |
| 09/13/2001 | CA2401549A1 G-protein coupled receptor related polypeptides |
| 09/13/2001 | CA2401541A1 Human protein kinases and protein kinase-like enzymes |
| 09/13/2001 | CA2401524A1 New ccr5 modulators: benzimidazoles or benzotriazoles |
| 09/13/2001 | CA2401454A1 G-protein coupled receptors |
| 09/13/2001 | CA2401398A1 Dna encoding human acid-sensing ion channel bnac4 (asic4) |
| 09/13/2001 | CA2401323A1 Treatment of diseases associated with cytokine production with inhibitors of the tec family of protein tyrosine kinases |
| 09/13/2001 | CA2400628A1 Use of tgf-beta antagonists to treat or to prevent loss of renal function |
| 09/13/2001 | CA2400504A1 Composition for the treatment of heart failure |
| 09/13/2001 | CA2399921A1 Protein tyrosine phosphatase polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399913A1 Adam polynucleotides, polypeptides, and antibodies |
| 09/13/2001 | CA2399111A1 New aza-indolyl derivatives |
| 09/13/2001 | CA2399055A1 Synergistic activation of regulatory elements by rel proteins and a steroid receptor |
| 09/12/2001 | EP1132389A1 New aza-indolyl derivatives for the treatment of obesity |
| 09/12/2001 | EP1132388A2 Hexahydropyrazolo[4,3-c]pyridine metabolites |
| 09/12/2001 | EP1132382A1 3-Oxy-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadazine-1,1-dioxide derivatives having diuretic and/or natriuretic activity |
| 09/12/2001 | EP1132098A1 Gene therapy for cerebrovascular disorders |
| 09/12/2001 | EP1132093A1 Preventives or remedies for myocarditis, dilated cardiomyopathy and cardiac insufficiency containing nf-kappa b inhibitors as the active ingredient |
| 09/12/2001 | EP1132092A1 Coupling factor 6 inhibitor and potentiator and use thereof |
| 09/12/2001 | EP1132086A2 Use of prostaglandin (PGE2) receptor 4 (EP4) selective agonists for the treatment of acute and chronic renal failure |
| 09/12/2001 | EP1131445A1 Human phospholipases |
| 09/12/2001 | EP1131436A1 Urotensins ii of mammals and their uses |